FutureMeds Appoints Małgorzata Herrera as Director of Global Feasibility and Proposals
Updated: Jan 24
Małgorzata Herrera joins FutureMeds as Director of Global Feasibility and Proposals. Małgorzata is a seasoned clinical research executive with almost 2 decades of experience.
As a Global Feasibility and Proposals leader, Małgorzata will streamline the feasibility processes across the rapidly growing organisation. This will ensure that FutureMeds continues to deliver high-quality results for its Sponsor and CRO partners, while providing patients with an exceptional clinical experience. She will report to Iwona Tongbhoyai, Vice President of Operations at FutureMeds.
“Malgorzata's long-term clinical research, global feasibility & proposal experience, strong leadership skills as well solution-, client- and patients-oriented approach will help FutureMeds to further optimise the feasibility & proposal process and provide solutions needed for studies, clients and patients alike. I am very happy to work again with Malgorzata. She is an exceptionally skilled professional with a great personality. It is great to have her in our dynamically growing FutureMeds team.”
- Iwona Tongbhoyai, Vice President of Operations at FutureMeds
Małgorzata comes with a wealth of knowledge and experience and has been part of the clinical research industry since 2006. She served in multiple roles before finding her true calling in late 2009. Working at Synexus and rising through the ranks, she built deep domain expertise in site operations, supervising feasibility and contractual processes.
In 2016 Małgorzata was promoted to lead the global feasibility department of Synexus. After the AES acquisition of Synexus, she was appointed Director of Feasibility in 2019. 13 months later, she was promoted to Senior Director of Feasibility at AES.
As part of the FutureMeds team, Małgorzata will be working closely with Iwona Tongbhoyai, Vice President of Operations and will be responsible for improving site feasibility, with a goal of speeding patient access to clinical trial participation and, ultimately, much-needed new treatments.
“I am immensely happy to join FutureMeds! Working closely with our partners, inspirational industry leaders and experienced FutureMeds professionals and developing treatments is hugely rewarding. When it comes to saving people's lives or improving their quality of life, these treatments can make all the difference.” commented Małgorzata.
FutureMeds is a fast-growing independent Site Management Organisation and currently operates 12 sites across 4 countries. It is already in the top tier of Dedicated Research Site Networks in Europe and its Dedicated Research Sites across the continent are currently involved in running clinical trials on behalf of its clients in pharma and CROs.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.